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Background: The most recently described phenotype associated with Cystic Fibrosis (CF) is reduced bone mineral density which results in
osteopenia and osteoporosis. The etiology of the early onset of osteoporosis in CF patients has remained to be established. It has been suggested
that inadequate nutritional absorption of essential fatty acids may play a role in the altered bone metabolism. In this study, we characterized the
protective effect of fenretinide [N-(4-hydroxyphenyl) retinamide], a vitamin A derivative, on the early onset of osteoporosis in cystic fibrosis
transmembrane conductance regulator knockout (Cftr-KO) mice.
Methods: Using micro-computed-tomography we examined the effect of fenretinide on the bone composition and architecture in a Cftr-KO mouse
model which was then confirmed with histological analyses. Plasma fatty acids were quantified using thin layer chromatography-ELISA method.
Results: Twice-weekly treatments with fenretinide, over four weeks dramatically increased trabecular bone volume compared to controls. This
increase in bone volume was also related to an increased concentration of ceramide in the plasma resulting in the down regulation of phospholipid-
bound AA in Cftr-KO mice.
Conclusions: To our knowledge, this is the first time that fenretinide's protective effect against osteoporosis has been demonstrated. The results of
this study strongly suggest that fenretinide has potential to be used as a prophylaxis by preventing the early onset of osteoporosis.
© 2007 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Osteoporosis; Cystic fibrosis; Arachidonic acid; Docosahexaenoic acid; Ceramide; Cftr-KO mice1. Introduction
One of the most recently described phenotypes that has been
associated with CF is reduced bone mineral density which
results in osteopenia and osteoporosis [1–5]. A number of
studies have documented a prevalence (40–70%) of decreased
bone density in the CF population [6]. A longitudinal study of
151 adults with CF showed that 34% of patients had a Z-score1
of −2 or less [7]. Bianchi and colleagues reported that 66% (90/
136) of children and young adults with CF (age 4–24) have low
bone mineral density [8]. However, a direct link between the⁎ Corresponding author. Research Institute of the McGill University Health
Center, 1650, Cedar Avenue, Room L11-218, Montreal, Quebec, Canada H3G
1A4. Tel.: +1 514 934 1934x44517; fax: +1 514 934 8260.
E-mail address: danuta.radzioch@muhc.mcgill.ca (D. Radzioch).
1 Z-score is the number of standard deviations above or belowwhat's normally
expected for someone of the same age, sex, weight, and ethnic or racial origin.
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doi:10.1016/j.jcf.2007.09.001CFTR gene dysfunction and osteoporosis remains to be elucidated
[9]. Currently, physicians prescribe a range of vitamins and
minerals including: vitaminD, calcium, vitaminK as prophylaxis.
Clinical trials are underway with the goal of finding new potential
treatments and that might prevent the development of osteopo-
rosis in CF patients including: anti-resorptive agents such as
bisphosphates, anabolic agents such as parathyroid hormone
(PTH) (extensively reviewed by Aris and colleagues) and human
recombinant growth hormones (hrGH) [10,11]. Recently, epide-
miological studies and experiments using animals and humans
have shown that a high concentration of n-3 essential fatty acids
(EFAs) improves bone metabolism [12].
EFA abnormalities in CF have been well-documented since
the early 60's [13]. Freedman and colleagues usedCftr-KOmice
to show that CF-affected organs have a significantly lower
concentration of docosahexaenoic acid (DHA) and a signifi-
cantly higher concentration of arachidonic acid (AA) [14]. DHAropean Cystic Fibrosis Society.
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functions and displays anti-inflammatory effects in CF. In
contrast, AA is an n-6 polyunsaturated fatty acid that has been
shown to regulate the production of prostaglandins and
leukotrienes, therefore acting as an agonist of the inflammatory
process [15]. DHA and AA are the “yin and yang” of fatty acid
metabolism, and disruption of the n-3 and n-6 EFA balance
results in a number of systemic abnormalities [16]. It has been
proposed that increased levels of AA might contribute to the
progression of CF lung disease, and that dietary supplementation
with high doses of DHA could correct this imbalance [17].
However, the effectiveness of this treatment option is compro-
mised in patients with CF due to the severe malabsorption of
lipids displayed by the majority of CF patients [18].
Treatment with fenretinide [N-(4-hydroxyphenyl) retina-
mide, 4-HPR], a semi-synthetic retinoid leads to the generation
of ceramides [19–21], and increases 12-lipoxygenase (12-
LOX), an enzyme that catalyzes the oxidation of phospholipid-
bound AA [22,23], suggesting that fenretinide may be able to
decrease AA concentrations. Sphingomyelinase, the enzyme
that catalyzes the formation of ceramides plays a crucial role as
an intracellular messenger in osteoblast differentiation from
stroma cells, suggesting that ceramides may also play an
important role in modulating bone metabolism [24]. Recently,
our laboratory reported that Cftr-KO mice have impaired levels
of ceramides and that treatment with fenretinide was able to
correct this impairment [25].
We hypothesized that treatment with fenretinide might be
able to prevent the development of osteoporosis by decreasing
AA concentrations and increasing ceramide concentrations.
Therefore the aim of the presented study was to assess the
protective role of fenretinide against CF related osteoporosis.
2. Methods
2.1. Mice
The inbredmice (11–14week old) used in our study were bred
in the animal facility of the Research Institute of the McGill
University Health Centre (from C57BL/6J breeding pairs
heterozygous at the Cftr locus). Age- and gender-matched
C57BL/6-Cftr+/+(WT) mice (n=16), and C57BL/6-Cftr−/−(Cftr-
KO) mice (n=16) were maintained in a murine pathogen- and
parasite-free environment. They were kept in cages with sterile
maple hardwood bedding (PWI, St-Hyacinthe, QC, Canada) and
housed in ventilated racks (Lab Products, Seaford, DE, USA).
The liquid diet was freshly prepared everymorning. Experimental
procedures with the mice were conducted in accordance with the
Canadian Council on Animal Care guidelines and with the
approval of the Animal Care Committee of theMcGill University
Health Center, Montreal, Quebec, Canada. Results were pooled
from 3 independent experiments.
2.2. Drug administration
Fenretinide powder was kindly provided by Dr. Robert Smith
from the NIH (Bethesda, MD, USA). Fenretinide was dissolvedin 95% ethanol to a 2 μg/μL concentration. Fourty μL of this
preparationwas incorporated into the Peptamen liquid diet (5mg/
kg per day per mouse). The prepared food containing fenretinide
was then stored in the dark at 4 °C for no more than 3–6 h before
its administration to the mice. To ensure that the entire drug dose
was consumed, the mice were given 10 mL of fenretinide-
containing Peptamen, which represents 2/3 of the daily mouse
food consumption with the completed dose, in the late afternoon.
The remaining 5mL of Peptamen (without fenretinide)was given
the following morning. Mice were treated twice a week for
4 weeks. During the treatment period each mouse was kept in a
separate cage. The diet for the mock-treated control group was
prepared and administered similarly to that described above, by
adding the same volume of ethanol to the Peptamen diet but
omitting the fenretinide supplementation (vehicle control).
2.3. Micro computed tomography (micro-CT)
Micewere euthanized usingCO2 inhalation and exsanguinated
by cardiac puncture. Femurs, tibiae and lumbar vertebrae were
extracted, stripped of soft tissue and fixed overnight in 4%
paraformaldehyde.Micro computed tomography (micro-CT) was
performed on the left femur after overnight fixation. The distal
metaphysis was scanned with a Skycan 1072 instrument (Sky-
scan, Antwerp, Belgium). Image acquisition was performed at
100 kVand 98 μA, with a 0.9° rotation between frames. The two-
dimensional images were used to generate three-dimensional
reconstructions to obtain quantitative data using the 3D Creator
software suppliedwith the instrument (ANT 3DCreator software,
Skyscan, Antwerp, Belgium). The SMI score is an algorithm
taking into account the change in surface area for the change in
radial expansion of trabecular plate-like and rod-like structures,
which is known as the “trabecular bone pattern factorq [26,27]. A
SMI score between 1 and 3 is then reported, as the value
approaches 3, the quality of the bone worsens.
2.4. Histological analysis
After overnight fixation in 4% paraformaldehyde and
rinsing in phosphate buffered saline (PBS), right femurs and
tibiae were embedded in polymethylmethacrylate (MMA) or a
mixture of 50% MMA and 50% glycolmethacrylate (GMA).
Serial 4- to 6-μm sections were cut on a modified Leica RM
2155 rotary microtome (Leica Microsystems, Richmond Hill,
Ontario, Canada).MMA-embedded tissues were stained with von
Kossa and toluidine blue, while 4 μmMMA-GMA sections were
stained with tartrate-resistant acidic phosphatase (TRAP). Images
were captured using a Carl Zeiss Microscope (Germany)
equipped with an AxioCam MRc camera. The left femur and
tibia and the lumbar vertebraewere decalcifiedwith 4%EDTA for
paraffin embedding after 14 days. Serial 5 μm sections were cut
and stained with haematoxylin and eosin (H&E). Osteoblasts lay
down new bone lamellae and are active in bone development and
in bone remodeling. Osteoblasts were defined as a single-
nucleated, rod shaped cells and were identified along the surface
of the trabecular lamellae. Osteoclasts have been shown to be
involved in bone resorption, by digesting the adjacent bone
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were much larger then osteoblasts and displayed typical
macrophage morphology.
2.5. Fatty acid analysis
Plasma was suspended in 1 mM butylated hydroxyanisole
(BHA) in chloroform and methanol (2:1 vol) until the analysis
was performed to ensure the integrity of the samples. Lipids
were extracted from plasma with chloroform/methanol (2:1), as
previously described [28]. Phospholipids were identified by thin
layer chromatography extraction. Diazomethane was used to
esterify the released fatty acids and the esters were identified by
GC/MS (Hewlett Packard5880A, WCOT capillary column
(Supelco-10, 35 m×0.5 mm, 1 μm thick)) using commercial
standards (Sigma-Aldrich, Oakville, ON, Canada).
2.6. Ceramide/sphingolipid analysis
Ceramide concentrations in the plasma of treated and
untreated mice were determined by an enzyme-linked immu-
nosorbent assay (ELISA), performed on lipid samples that were
separated by thin layer chromatography (TLC), as have
previously described and validated in detail elsewhere [29].
Briefly, lipids were extracted from lung homogenates with
chloroform/methanol (2:1) containing 1 mM butylated hydro-
xyanisole (BHA) [30]. The lipid fractions were then dried under
nitrogen and resuspended in heptane [31]. Phospholipid
separation was performed by TLC, detected by iodine. On
these separated lipid samples, the concentration of ceramide
was determined by ELISA [32,33]. The phospholipids from the
dry silica were re-suspended in ethanol and used to coat Nunc
plates specific for lipid binding. Plates were then washed,
incubated with blocking buffer for 1 h at 37 °C (PBS, 0.1%
Tween 20), and 1% bovine serum albumin (BSA; Sigma,
Oakville, ON), and incubated with murine anti-ceramide IgM
(Sigma-Aldrich) antibody (Ab) for 1 h at 37 °C.
The plates were then washed and incubated with peroxidase-
conjugated anti-mouse IgM Ab for 1 h at 37 °C. Finally, the
plates were incubated with the peroxidase substrate (TMB;
Roche, Laval, QC). The intensity of the colorimetric reaction
was determined by spectrophotometry at 405 nm. The levels of
ceramide were calculated with reference to a standard curve
prepared using purified ceramide (Sigma-Aldrich). Phosphate
levels were assessed, as previously described, using the
PiBlue™ Phosphate assay kit (Boehringer Ingelheim, Ingel-
heim, Germany), according to the manufacturer's instructions.
2.7. Statistical analyses
Data was analyzed using GraphPad Prism Version 4.03
software (GraphPad Software, San Diego, California, USA).
Statistically significant differences between the medians of
studied groups were evaluated using the non-parametric Mann–
Whitney U test when comparing two groups (Fig. 3). Pair-wise
multiple comparisons were used to evaluate the differences
between multiple groups using Kruskal–Wallis on ranks and theDunn's multiple comparison post test between groups.
Significance was set at a two-tailed P value of ≤0.05.
3. Results
3.1. Trabecular bone density
Trabecular bone density was measured using micro-CT scans
and histology. Fig. 1A illustrated the micro-CT scans of the
trabecular bones isolated from Cftr-KO mice femurs and their
littermate controls (WT). Results illustrated clearly show
evidence of reduced trabecular bone in the Cftr-KO compared
to their WT littermate controls. These results also clearly
demonstrate that twice-weekly treatment with fenretinide over
the course of four weeks (total 8 doses) was able to completely
eliminate any signs of osteoporosis in the trabecular bone of
Cftr-KO mice. Representative 3D reconstructions and 2D cross-
sectional scans demonstrate that, before fenretinide treatment,
Cftr-KO mice have virtually no trabecular bone (highlighted in
black boxes) evident in the cross-sectional image as compared to
WT controls. After treatment with fenretinide there is a dramatic
increase in trabecular bone in theCftr-KOmice compared to their
WT controls. Micro-CT results were compared with histochem-
ical staining of non-decalcified bone using von Kossa stain,
which stainsmineralized bone as shown in Fig. 1B.Cftr-KOmice
clearly illustrate a decrease in trabecular bone (highlighted in
the black box) compared to the WT controls, meanwhile when
Cftr-KO mice are treated with fenretinide, the early onset of
reduced bone mineral density is avoided.
3.2. Bone composition and architecture
To address the osteoporotic changes from the composition
and architecture point of view, the trabecular bone was
quantified. The following parameters: bone volume fraction
(BV/TV%), structural model index (SMI) trabecular separation
(TS), and trabecular thickness (TT) were calculated from the left
femur using micro-CT scans.
Our results illustrate a significant (p=0.005) lower amount of
BV/TV% in the Cftr-KO mice as compared to WT vehicle-
controls as shown in Table 1. Interestingly, this difference is
eliminated when Cftr-KO mice are treated with fenretinide (2.2-
fold increase), which increases their BV/TV% to a level
comparable to those observed in the WT mice. This increase in
BV/TV%was associatedwith a statistically significant increase in
bone volume (BV) (p=0.005) and bone number (TN) (p=0.007).
Fenretinide treatment increased BV, 2.8-fold and TN, 2.0-fold
compared to Cftr-KO vehicle-control mice. SMI scores (de-
scribed in detail in the Methods section) shows a significant
(p=0.012) difference between WT and Cftr-KO vehicle-control
mice. However, when the Cftr-KO mice are treated with
fenretinide, the SMI score is significantly lowered (p=0.012) to
the level of the WT mice resulting in no significant difference
between the WT (vehicle controlled) and Cftr-KO (treated).
Cftr-KOmice display a significantly (p=0.009) higher degree of
separation when compared to WT vehicle-control mice. How-
ever, when mice are treated with fenretinide this difference in
Fig. 1. A. micro-CT image of femur. Femurs of 5 to 6 mice per group were dissected free of soft tissue, fixed overnight before scanning on a Skyscan 1072 static instrument
equipped with 3D Creator analytical software. Representative 3D reconstructions and 2D cross-sectional scans demonstrate a clear difference between vehicle-treated WT
and Cftr-KO mice. Cftr-KO mice have much less bone volume then their WT controls. The solid black box illustrates the area of the bone analyzed by micro CT.
Fenretinide's positive effect in increasing Cftr-KO bone volume is highlighted by the black square outline on the right. B. von Kossa stains of femur. Bones were
embedded in MMA and stained with von Kossa. These were used to confirm the amount of mineralized bone (black stain) to the micro-CT images. Representative slides
are shown.
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thickness was also assessed however there was no statistical
difference in either the vehicle-controlled groups nor the treated
animals. All the micro-CT results observed from the femur were
then confirmed by analysis of the L3–L5 vertebrae, which is rich
in trabecular bone (data not shown).3.3. Increased osteoblast formation
To establish whether the increase in bone volume observed
in the fenretinide-treated Cftr-KO mice results from more
efficient bone formation or of less efficient bone resorption we
counted the number of osteoblast and osteoclast cells. Table 2
Table 1
Treatment with fenretinide improves bone composition and architecture in Cftr-KO mice
Vehicle (n=6) FEN (n=5) p value (^)
Median (25%–75%) Median (25%–75%) Vehicle vs FEN
BV/TV (%) WT 7.78† (5.04, 11.72) 10.20 (8.90–12.59) ns
Cftr-KO 3.82†^ (2.11, 4.85) 8.31^ (7.90–11.95) ^0.007
† p=0.005 WT-vehicle vs. KO-vehicle
BV (mm3) WT 0.26¥ (0.13, 0.36) 0.31 (0.24, 0.36) ns
Cftr-KO 0.08¥^ (0.07, 0.12) 0.23^ (0.22, 0.34) ^0.005
¥ p=0.005 WT-vehicle vs. KO-vehicle
TN (1/mm2) WT 1.61§ (1.07, 2.44) 2.12(1.78, 2.51) ns
Cftr-KO 0.80§^ (0.52, 1.06) 1.62^ (1.54, 2.49) ^0.007
§ p=0.005 WT-vehicle vs. KO-vehicle
SMI WT 2.13† (1.80, 2.40) 1.90 (1.44, 2.25) ns
Cftr-KO 2.46†^ (2.30, 2.63) 2.16^ (1.85, 2.27) ^0.012
† p=0.012 WT-vehicle vs. KO-vehicle
TS (mm) WT 0.254⁎ (0.194–0.277) 0.201 (0.199–0.227) ns
Cftr-KO 0.284⁎^ (0.272–0.377) 0.241^ (0.201–0.259) ^0.009
⁎ p=0.026 WT-vehicle vs. KO-vehicle
TT (mm) WT 0.048 (0.046–0.049) 0.048 (0.047–0.053) ns
Cftr-KO 0.046 (0.042–0.048) 0.049 (0.046–0.054) ns
Table 2
Treatment with fenretinide number of osteoblasts in Cftr-KO mice
Vehicle (n=4) FEN (n=5) p value (^)
Median
(25%–75%)
Median
(25%–75%)
vehicle vs
FEN
Osteoblast number WT 118⁎ (103–140) 123 (112–143) ns
Cftr-KO 71.5⁎^ (56–86) 110^ (105–147) ^0.016
⁎p=0.029 WT-vehicle vs KO-vehicle
Osteoclast number WT 45.5 (43–50) 50 (44–64) ns
Cftr-KO 50.5 (34–66) 54 (48–60) ns
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per animal in each group fromH&E stained slides. Our analysis
clearly demonstrates a striking decrease in the number of
osteoblasts between the Cftr-KO compared to the WT mice
(p=0.029). Following treatment with fenretinide a significant
increase in the number of osteoblasts in the Cftr-KO mice
treated as compared to Cftr-KO vehicle-control mice
(p=0.016). Interestingly, no significant difference in number
of osteoclasts was found between the fenretinide-treated and
untreated Cftr-KO and WT. This finding was corroborated
using TRAP staining, as shown as Fig. 2, where the pink stain is
positive for tartrate-resistant acidic phosphatase, an enzyme
that is specific for osteoclasts cells. No difference between the
concentrations of TRAP staining in the Cftr-KO mice
compared to the WT controls or fenretinide-treated animals
was found.
3.4. Essential fatty acid profiles
Fig. 3 panels A–C represent the lipid profiles (AA, DHA, and
the AA/DHA ratio) of vehicle-control mice. In all groups a
statistical significance is observed between the WT and the Cftr-
KO mice (p=0.0002, pb0.0001 and p=0.0002 respectively).
The data in this study illustrates that only 8 treatments with
fenretinide effectively reduce the excessive amount of AA
consistently found in the plasma of Cftr-KO mice, resulting in
no significant difference between WT mice and Cftr-KO mice as
shown in Fig. 3D (p=NS).Cftr-KOmice treated with fenretinide
also show a positive trend with a 2 fold increase in DHA
concentrations then vehicle-control Cftr-KO mice however a
statistically significant difference was still observed between the
WT and Cftr-KO treated mice as shown in Fig. 3E. When
comparing the AA/DHA ratio of vehicle-controlCftr-KO animals
to fenretinide-treated Cftr-KO treated mice, it was clearly evident
that fenretinide treatment had the ability to decrease the ratio by
half, however there was still a statistical difference between the
WT and Cftr-KO treated groups (Fig. 3F).3.5. Ceramide concentrations
Ceramide levels in the untreated Cftr-KO mice were
significantly lower (pb0.0001) as compared to their WT
littermate controls as shown in Fig. 4. After 4 weeks of
semiweekly treatment with fenretinide, the ceramide levels in
the treated Cftr-KO mice increased 2.5 fold compared to
untreated Cftr-KO mice (p=0.0002). Although fenretinide did
not completely correct the ceramide impairment in the Cftr-KO
mice the partial correction was closely associated with the
observed protective effect of fenretinide treatment against
osteoporosis in these mice.
4. Discussion
The data demonstrated in this manuscript illustrates that
twice-weekly treatments with fenretinide for 4 weeks, leads to
the prevention of the low trabecular bone volume observed in
Cftr-KO mice. This increase in trabecular bone density was
associated with an increase concentration of ceramide and the
down regulation of AA in the plasma. To our knowledge, this is
the first time that fenretinide has been documented as an
effective prevention of the early onset of osteoporosis in CF.
The etiology of early onset osteoporosis in CF patients is not
established and most likely involves the complex interactions
among several biochemical pathways [34–36]. Aris and
Fig. 2. Osteoblast and osteoclasts cells quantification in the femur. Bones were
decalcified; embedded in paraffin and stained with H&E (inlets). Osteoblasts
were identified as single-nucleated, rod shaped cells attached to the trabecular
bone as shown by black arrow. Osteoclasts were defined as large multinuclear
round (macrophage type) cells attached to the trabecular bone. Multiple slides
were used to count the number of osteoblasts and osteoclasts (a representative
slide is shown as inlet to TRAP stained slides). Slides were counted at 400×
magnification. TRAP staining. Bones were embedded in MMA and stained with
TRAP. Multiple slides were analyzed to identify and quantify osteoclasts present
in each slide (a representative slide is shown at 200× magnification).
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with CF as the result of several factors including: malnutrition,
pancreatic insufficiency, vitamin insufficiency, diabetes, gluco-
corticoids, inflammatory cytokines, and sex hormone insufficien-
cy [37]. It seems reasonable to assume that the lipid imbalance,
one of the hallmarks of CF, would also play an important role in
the etiology of osteoporosis. However, all of these factors are
intertwined making it difficult to decipher the exact cause,
especially when there has been no direct link established between
the CFTR gene mutations and reduced bone volume.
Research in the CF field was greatly facilitated when the
CFTR gene was first cloned, which led to the creation ofCftr-KO
mice. Since the first generation of Cftr-KO mice, there have been
multiple successful attempts to improve this model, and it is now
better suited to the study of CF phenotypes and their treatment
[38]. Overall, CF mice still represent the most useful and cost-
efficient animal model available to study such a multifaceted and
devastating disease. We have previously reported that the Cftr-
KO mouse model develops spontaneous inflammatory lung
disease[39–42]. In addition, we have recently demonstrated that
they also exhibit an imbalance between DHA and AA, similar to
CF patients [29]. Therefore, it may also represent a very goodmodel for studying other CF related phenotypes. Although
osteoporotic changes were previously documented in 3 week old
CF mice by Dif and colleagues [43], our study shows for the first
time using micro-CT technology that adult Cftr-KOmice display
a significant defect in BV/TV% compared to their littermate
controls. In this manuscript we used our CF mouse model to
characterize in a detailed manner the early onset of osteoporosis
and to assess the efficiency of fenretinide in treating this
condition. Our research demonstrated that Cftr-KO mice develop
the osteoporosis phenotype, showing extremely low bone volume
and structural abnormalities. Our results suggest that fenretinide
not only corrects the quantity of bone but also the quality of the
bone structure as well. It is worth noting that using the mouse
model to study the etiology of this condition has advantages over
human studies because Cftr-KO mice, in contrast to CF patients,
are not treated with antibiotics and glucocorticoids. Additionally
there is no 1, 25 vitamin D deficiency present in ourCftr-KOmice
(data not shown), which allows us to rule out these factors
involvement in the development of bone disease. We also
measured the change in weight of the Cftr-KO mice before and
after treatment of the vehicle-control group and compared it to the
treated group and found no statistically significant change in
growth caused by the treatment.
A skeletal system does not only serve as mechanical support,
but rather functions as an active organ that regulates balance and
interactions between both local and systemically circulating
factors. Bone remodeling is regulated by a number of hormones,
cytokines, growth factors, and prostaglandins [44]. Defective
fatty acid metabolism has been linked to inflammatory diseases
such as asthma and rheumatoid arthritis as well to osteoporosis
in elderly people [45–49]. More recently, Gronowitz and
colleges reported that the essential fatty acid (n-6/n-3) ratio of
children with cystic fibrosis influences bone mineral density,
indicating that fatty acid status is important for bone growth
[50]. It has previously been suggested that an effective decrease
in phospholipid-bound AA concentrations could consequently
lead to a decrease in the level of prostaglandin production in
bones and an increase in bone formation by improving
osteoblast cell function in cell cultures and in periodontal
disease in humans [51]. Fenretinide has been shown to catalyze
the oxidation of AA so that it can be moved out of the
phospholipid membrane and converted to a less harmful
metabolite 12-Hydroxyeicosatetraenoic acid (12-HPETE/12-
HETE) via 12-LOX intracellularly [52]. Ichikawa and collea-
gues demonstrated that the regulation of the human LOX12
gene is closely associated with bone mineral density [53]. Our
results demonstrate that treatment with fenretinide is able to
normalize the levels of AA in the plasma of Cftr-KO mice.
DHA concentrations were also increased in fenretinide-treated
animals, which positively affected a significant decrease in the
abnormal AA: DHA ratio typically observed in the Cftr-KO.
Taken together, these results demonstrate not only that
fenretinide has a protective effect on bone density in Cftr-KO
mice, but also provide clues regarding its mechanism of action.
Reports had suggested that sphingolipids and ceramide have
an important role in modulating bone metabolism [30,50].
Recently our laboratory published Cftr-KO mice have a
Fig. 3. Lipid profile of Cftr-KO and WT vehicle-control and fenretinide-treated. Mice A–C. Vehicle-control. Concentration's of AA (ng/μg of phosphate), DHA (ng/
μg of phosphate) and the AA/DHA ratio was assessed in WT and Cftr-KO vehicle-control mice. (†) indicates statistical significance between untreated WT and Cftr-
KO vehicle controls. The line represents the median. D–F. Fenretinide Treated. After a total of 8 treatments with fenretinide, AA in the plasma of Cftr-KO mice was
decreased significantly to the level observed in the WT. A significant difference between treated Cftr-KO animals and WTanimals was no longer detectable (D). After
treatment with fenretinide, DHA in the Cftr-KO mice increased 2-fold, illustrating a positive trend (E). Treatments with fenretinide, improved the AA/DHA ratio 2
fold. (†) indicates statistically significant difference between WT and Cftr-KO treated mice. The line represents the median.
Fig. 4. Ceramide levels in Cftr-KO and WT vehicle-control and treated with
fenretinide. Ceramide levels (ng/μg of phosphate) were assessed in plasma
isolated fromWTand Cftr-KO mice. The ceramide levels in the plasma samples
were statistically different pb0.0001(⁎) between WT and Cftr-KO vehicle-
control mice. Following treatment with fenretinide, the ceramide levels in the
Cftr-KO mice significantly increased pb0.0002(^).
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phenotype [25]. Our results show, ceramide levels increased 2.5
times after only 8 treatments with fenretinide and subsequently,
when analyzing the micro-CT data, we observed that fenretinide
treatment also significantly increased the trabecular bone
volume and quality of the bone.
Matrix vesicles are cell-derived microstructures involved in
the initiation of bone mineralization, cartilage and dentin. They
are rich in 5-AMP-ase [54] and sphingomyelin, both of which
are concentrated in plasma membranes. These membranes are
saturated with phospholipids which act as trap for calcium ions
[55]. During normal calcification, there is a major influx of
calcium and phosphate ions into the cell accompanied by cellular
apoptosis and matrix vesicle formation [56]. Matrix vesicles
separate from the plasma membrane at sites where there are
interactions with the extra cellular matrix, to nucleate mineral
formation. These processes coordinate the mineralization during
bone development. Kozawa and colleagues hypothesized that
sphingomyelinase plays a crucial role as an intercellular
messenger in osteoblast differentiation [24]. Our findings
strongly suggest that ceramide plays an important role in
modulating bone metabolism and that osteoblast proliferationseems to be increased as well due to fenretinide's effects. We
have also proposed a possible mechanism through which
fenretinide may be acting to exert this positive effect on bone
metabolism as summarized in Fig. 5.
Fig. 5. Fenretinide prevents the development of osteoporosis in Cftr-KO mice The chart summarizes the findings from this manuscript. All values are quoted as ranges
(minimum and maximum). The diagram depicts biochemical links that might be involved in a fenretinide-induced increase of bone formation in the Cftr-KO mice.
Fenretinide stimulates the production of sphingomyelin that subsequently increases ceramide concentrations. Increasing ceramide (a lipid secondary messenger)
stimulates lipoxygenase-12 (LOX-12), an enzyme that catalyzes the oxidation of arachidonic acid (AA) to leave the phospholipid bi-layer and become a less harmful
metabolite 12-Hydroxyeicosatetraenoic acid (12-HPETE/12-HETE) intracellular.
229Z. Saeed et al. / Journal of Cystic Fibrosis 7 (2008) 222–230Overall, treatment with fenretinide represents a unique
prophylaxis treatment option by directly increasing ceramide
levels, which directly or indirectly decreases excessive AA and
consequently increases trabecular bone volume. Based on the
results presented in this manuscript, it is clear that fenretinide
has potential as a treatment for CF patients, due to its protective
role in early onset osteoporosis. It is especially promising since
this drug has been reported to have only very mild side effects
and has already been approved and currently in clinical trials to
treat other disorders, such as neuroblastoma and other cancers.
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